← Back to Bills
H.R. 1796House119th Congress (2025-2027)In Committee

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Sponsored by John JamesRep. John James (R-MI)
Introduced March 3, 2025

AI-Generated Summary

Updated November 24, 2025 at 2:16 AM UTC

The bill amends the Public Health Service Act to reauthorize and expand a federal demonstration program focused on sickle cell disease. It broadens the program’s scope to treat the disease and its complications, gives the agency more flexibility in how it provides funding, and raises the annual budget to about $8.2 million for the 2025‑2029 period. It also expresses Congress’s desire for more research into hereditary blood disorders.

Key Provisions

  • Changes the program’s purpose to cover treatment of sickle cell disease and the prevention and treatment of its complications.
  • Allows the Health Service to fund the program through grants, contracts, or cooperative agreements rather than only contracts.
  • Increases the authorized funding level to $8,205,000 per year for fiscal years 2025‑2029 (up from $4,455,000 for 2019‑2023).
  • Adds a congressional statement encouraging additional research into the causes and cures of heritable blood disorders, including sickle cell disease.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
HouseIntro Referral Latest Action

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

March 3, 2025

View full timeline
HouseIntro Referral

Introduced in House

March 3, 2025

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

March 3, 2025

Bill Text

Latest available legislative text

Reading Mode
Latest
Raw Text PDF XML
Introduced in HouseIssued March 3, 2025

I

119th CONGRESS

1st Session

H. R. 1796

IN THE HOUSE OF REPRESENTATIVES

March 3, 2025

Mr. James (for himself, Mr. Veasey, Mr. Carter of Louisiana, Mr. Davis of Illinois, and Mrs. Kiggans of Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

1.

Short title

This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025.

2.

Sickle cell disease treatment prevention and treatment

(a)

In general

Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—

(1)

in paragraph (1)(A)(iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;

(2)

in paragraph (2)(D), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;

(3)

in paragraph (3)—

(A)

in subparagraph (A), by striking enter into a contract with and inserting make a grant to, or enter into a contract or cooperative agreement with,; and

(B)

in subparagraph (B), in each of clauses (ii) and (iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; and

(4)

in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2025 through 2029.

(b)

Sense of Congress

It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.